Digital breast tomosynthesis, which produces three-dimensional images of the breast, may be more accurate than mammography in detecting breast cancer but may also expose women to more radiation.
Irradiation from diagnostic computed tomography (CT) scans is associated with an increased risk of cancer among children and adolescents exposed to CT.
Frequent heartburn is associated with a higher risk of cancers of the pharynx and larynx, which may be reduced by the use of antacids.
The initial results from the National Lung Screening Trial concur with the literature, with more positive screening results, diagnostic procedures, and lung cancers detected with low-dose computed tomography vs. chest radiography screening.
Among men with nonmetastatic prostate cancer the risk for other-cause mortality increases with the number of comorbid conditions, particularly in older men.
The risks of metastasis and death associated with cutaneous squamous cell carcinoma are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond fat, poor differentiation, and location.
Men's middle-aged fitness level may protect against cancer.
Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).
Older individuals with nonmelanoma skin cancer seem to have a significantly reduced risk of developing Alzheimer's disease.
For unresectable lung tumors, the combination of segmental pulmonary arterial chemoembolization (SPACE) and percutaneous radiofrequency (RF) ablation helps achieve better local tumor progression rates than RF ablation alone.
The FDA has approved Bayer's Xofigo for the treatment of advanced prostate cancer with bone metastases.
The cobas EGFR Mutation Test has been approved to identify patients with non-small cell lung cancer who are candidates for receiving Tarceva as first-line treatment.
The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
For cancer patients, creative arts therapies (CATs) are associated with improvements in psychological symptoms and quality of life.
For patients undergoing pacemaker or implantable cardioverter-defibrillator surgery, the incidence of clinically significant pocket-device hematoma is significantly reduced with continued warfarin therapy vs. heparin bridging.
For patients with metastatic prostate cancer, visiting the emergency department over the weekend is associated with increased odds of mortality.
For patients with chronic neutrophilic leukemia and atypical (BCR-ABL1-negative) chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor (CSF3R) are common.
Regardless of patient life expectancy, most cases of nonmelanoma skin cancer are treated surgically.
Minimal Dose Computed Tomography Scan of the Chest (MnDCT) delivers a radiation dose comparable to that of chest X-ray, with greater sensitivity for detecting new or recurrent lung cancer.
Phase 3 trial evaluating Vectibix vs. Erbitux for the treatment of chemo-refractory metastatic colorectal cancer meets its primary endpoint for overall survival.
Oncotype DX, the first-of-its-kind biopsy-based prostate cancer test, is now available to help physicians and their patients choose the most appropriate treatment.
The U.S. FDA has proposed an order to reclassify sunlamp products from a low-risk to a moderate-risk device, which would require comprehensive risk labeling on such products.
The FDA is alerting health care professionals of possible medication errors resulting from confusing generic names for Kadcyla (ado-trastuzumab emtansine) and Herceptin (trastuzumab).
The incidence of testicular germ cell tumors increased from 1992-2009, especially among Hispanic men.
New AUA guidelines for prostate cancer screenings increase the recommended age from 40 to 55, and recommend screenings every two years instead of annually.
For patients with benign radiologic-pathologic concordant minimally invasive breast biopsy, interval imaging performed after <12 months has a low yield and high cost for detection of breast cancer.
Adult acute myeloid leukemia (AML) genomes have an average of 13 mutations, and almost all cases have at least one nonsynonymous mutation in a category of genes relevant for pathogenesis.
Janssen Research & Development announced that the FDA granted daratumumab Breakthrough Therapy Designation for the treatment of patients with multiple myeloma.
Lymphoseek Injection is now available for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek was approved by the FDA in March 2013.
Women who have received cosmetic breast implants may have an increased risk of diagnosis at a non-localized stage of breast cancer, and seem to have worse breast cancer survival.
Female smokers seem to be more susceptible to colon cancer than male smokers, particularly to proximal colon cancer.
Having more comprehensive discussions about colorectal cancer screening with primary care providers is associated with increased odds of screening.
Among pediatric cancer patients who receive medications at home, errors are common, with a rate of 3.6 errors with injury per 100 patients.
Men and women with a history of non-melanoma skin cancer (NMSC) are at modestly greater risk of secondary cancers at other sites.
Mammography with integrated two-dimensional (2D) imaging together with tomosynthesis with three-dimensional (3D) imaging is associated with improved breast cancer detection.
For young women with breast cancer, a longer treatment delay time is associated with decreased survival; and women with early-stage breast cancer with Medicaid are more likely to undergo mastectomy than those with private insurance.
In men with an initial benign biopsy or transurethral resection of the prostate, obesity is associated with the presence of precancerous lesions in the initial biopsy and a higher risk of developing prostate cancer.
The FDA has designated Merck's lambrolizumab (MK-3475) as Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor.
For HER2-mutated non-small-cell lung cancer, half of tumors are detected at stage IV, and anti-human epidermal growth factor receptor 2 (HER2) treatments are associated with encouraging response rates and disease control rates.
There has been no change in mammography screening rates among women aged 40 years or older following publication of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendations.
For patients with stage I and II primary tonsil carcinoma, radiotherapy after tonsillectomy is associated with improved overall survival and disease-specific survival, compared with radiotherapy after biopsy.
After elective colectomy, patients with diverticular disease have worse outcomes and higher costs than patients with colon cancer but better outcomes and lower costs than patients with inflammatory bowel disease.
The diagnostic accuracy of smartphone applications that analyze photos of pigmented skin lesions for melanoma risk is highly variable and incorrectly classifies about a third of melanomas as benign.
For older men with abnormal prostate-specific antigen (PSA) levels, performance of prostate biopsies is uncommon and decreases with advancing age and worsening comorbidity.
The estimated sizes of lung nodules and mediastinal lymph nodes vary considerably with the radiation dose of chest computed tomography examinations.
Prostate-specific antigen concentrations in midlife can be used to predict the long-term risk of prostate cancer metastasis or death from prostate cancer.
The use of computer-aided detection for screening mammography has increased in prevalence and is associated with increased diagnosis of ductal carcinoma in situ (DCIS).
About 25% of women with breast cancer either never initiate adjuvant endocrine treatment or stop treatment prematurely.
For men undergoing routine surgical treatment for localized cancer of the prostate, robot-assisted radical prostatectomy does not result in better functional outcomes compared to laparoscopic radical prostatectomy.
The incidence of pediatric melanoma has increased by about 2% per year, and this incidence trend is influenced by gender, age, and stage at diagnosis, primary site, and ultraviolet-B exposure.
Progressive disease cannot be reliably predicted by patient, clinical, or procedural factors in patients receiving regional therapy for advanced melanoma of the extremities.
Optimal breast cancer screening should be personalized for each woman and may go beyond mammography.
The FDA has granted Fast Track designation to Elorac's naloxone topical lotion, an opiate antagonist with no agonist activity, for the relief of pruritus in patients with cutaneous T-cell lymphoma.
Despite improvements in aspects of cancer prevention and early detection, American Cancer Society urged more systematic efforts to reduce tobacco use and obesity, and expand the use of screening tests could prevent much of the suffering and death of cancer.
Two popular U.S. parenting magazines give little attention in terms of articles or advertisements to preventing skin cancer risk.
Toenail selenium, which reflects long-term selenium intake, is associated with a decrease in the risk of advanced prostate cancer, especially during later follow-up.
The FDA has granted a Breakthrough Therapy designation to Pfizer's palbociclib, an oral and selective inhibitor of CDK 4 and 6 that is a potential treatment for breast cancer patients.
For patients with papillary thyroid cancer (PTC), the presence of the BRAF V600E mutation is associated with increased cancer-related mortality.
Radiation-associated heart disease correlates with an increased risk of death in patients undergoing cardiothoracic surgery.
Moderate alcohol consumption before diagnosis of breast cancer is associated with modest improvement in disease-specific survival, although overall consumption before and after diagnosis are not linked to disease-specific survival.
Not enough evidence exists to determine the benefits and harms of primary care screening of all adults for oral cancer, according to a new report.
Although melanoma survivors tend to engage in more sun protection practices than the general population, many do not seek shade and never wear sunscreen.
Increased exposure to air pollution during pregnancy and the first year of life is associated with an increased risk of pediatric acute lymphoblastic leukemia, germ cell tumors, and retinoblastoma.
Smokers who smoked within five minutes after waking have higher levels of tobacco smoke carcinogen and may be at higher risk for lung and oral cancer.
A two-step immunotherapy approach and a novel antibody-drug conjugate, DMUC5754A, show promise for advanced ovarian cancer.
Smoking is tied to significantly shorter disease-free survival and time to recurrence in patients undergoing treatment for stage III colon cancer.
There is a significantly increased lifetime risk of cancer for individuals exposed to polycyclic aromatic hydrocarbons (PAHs) associated with coal-tar-sealed pavement.
"Never events," ten hospital-acquired conditions deemed by the Centers for Medicare and Medicaid Services as being reasonably preventable, are rare in patients with bladder cancer who have undergone radical cystectomy.
Results from interim analysis demonstrated that Lymphoseek met the primary efficacy endpoint of accurately identifying sentinel lymph nodes in subject with squamous cell carcinoma of the head or in the mouth, as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck.
In patients with metastatic hormone-sensitive prostate cancer, intermittent androgen deprivation is associated with slightly, but not significantly, worse survival than continuous androgen deprivation.
Over the last 30 years, the incidence of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection has steadily declined, most likely due to a combination of factors.
The U.S. Preventive Services Task Force recommends that BRCA1 and BRCA2 genetic testing be limited to women whose family histories are associated with an increased likelihood of having BRCA mutations.
Available screening and identification of human papillomavirus likely contributed to the increased incidences of squamous cell carcinoma of the anal canal and anal carcinoma in situ after 1997.
Postmenopausal hormone therapy with estrogen plus progestin is associated with an increased risk of breast cancer.
Multiple cervical cancer screening strategies that maximize early detection of high-grade disease without excessive increases in initial testing appear to be most effective.
A test that measures four serum metabolites can accurately distinguish patients with pancreatic cancer from healthy people and patients with pancreatitis.
DNA-based testing with Hybrid Capture 2 assay is more accurate than repeat cytology in identifying women with cervical cancer when their initial Pap smear shows atypical squamous cells of undetermined significance.
Using intravenous administration of Reolysin in combination with carboplatin and paclitaxel, Oncolytics Biotech says its Phase 2 single arm study has met the primary overall statistical endpoint in patients with squamous cell carcinoma of the lung.
The cell-cycle progression gene panel is useful to improve the risk stratification for men with even low-risk, clinically localized prostate cancer.
The FDA has approved Abbott's Architect AFP, a test to help detect serious birth defects and the progression of testicular cancer. Alpha-fetoprotein (AFP) is a biomarker that can identify the progress of diseases or conditions as well as evaluate the effectiveness of treatments.
Trovagene has released a urine-based molecular human papillomavirus (HPV) test designed to identify the presence or absence of 15 known high-risk HPV strains using proprietary DNA sequences.
Cancer patients with high weight loss, low muscle index, and low muscle attenuation have a poor prognosis--regardless of body mass index.
For children, inherited genetic variants correlate strongly with susceptibility to acute lymphoblastic leukemia.
For patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU), the impact of smoking is gender specific, with worse outcomes for females than for males.
RedHill Biopharma and IntelGenx has submitted a New Drug Application to the FDA seeking marketing approval for acute migraine treatment drug RHB-103—a proprietary, oral thin film formulation of rizatriptan. This submission was based on a successful bioequivalence clinical trial.
For African-Americans, who are at elevated prostate cancer risk, baldness at age 30 correlates with prostate cancer, with frontal baldness linked to increased odds of high-stage and high-grade disease.
Lynch syndrome carriers have about a two-fold increased risk of prostate cancer.
A false-positive test result from screening mammography is not harmless and can result in negative long-term psychosocial consequences.
For patients with bladder cancer, genetic variants in the regulator of G-protein signaling pathway are associated with risk, recurrence, progression, and death.
Five patients with relapsed B cell acute lymphoblastic leukemia (B-ALL) quickly achieved complete remission after treatment with autologous engineered T cells.
At no age is there an overall survival benefit associated with bilateral oophorectomy compared with ovarian conservation at the time of hysterectomy for benign disease.
Due to lack of sterility assurance, Clinical Specialties is voluntarily recalling all lots of sterile products that were repackaged and distributed by the pharmacy. This recall follows the company's recall of Avastin unit dose syringes on March 18th.
A new position statement published by The Endocrine Society recommends that estradiol measurement assays and reference ranges be standardized and that the health care community work toward improving the accessibility of accurate estradiol testing methods.
Subjects who are enrolled in the Atherosclerosis Risk in Communities (ARIC) study and are meeting goals for 6-7 ideal health metrics have a 51% lower risk of incident cancer than those not meeting any goals for ideal health metrics.
Proteo's Elafin has been granted orphan drug designation by the FDA for prevention of inflammatory complications of transthoracic esophagectomy. The orphan designation provides U.S. market exclusivity for a seven-year period upon marketing approval for the designated indication.
After reports surfaced of five intraocular infections at a physician's office, Clinical Specialties is undertaking a voluntary recall of Avastin unit dose syringes. The sterile syringes were being used solely for an off-label indication by an ophthalmologist for macular degeneration.
Top-line results from the Phase 3 trial of Amgen's talimogene laherparepvec, being studied for the treatment of unresected stage IIB, IIIC or IV melanoma, have been announced.
Women who are 50-74 years old can safely undergo mammography every two years instead of annually. Younger women (40-49 years old) should only undergo annual mammography if they have extremely dense breasts.
Ecological evidence does not definitively link the decline in the use of hormone replacement therapy to a fall in the incidence of breast cancer.
Nightshift work may be associated with an increased risk of ovarian cancer. The risks were observed only for women aged 50 years and older, and for invasive and borderline tumors with serous and mucinous histologies.